Anastrozole

Drugs of Today

Volumn 41, Issue 4, 2005, Pages 227-239

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CORTICOSTEROID; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; GOSERELIN; KI 67 ANTIGEN; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; VOROZOLE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ASTHENIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLLES FRACTURE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; HEADACHE; HEART MUSCLE ISCHEMIA; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERTENSION; INCREASED APPETITE; MOOD DISORDER; NAUSEA; PERIPHERAL EDEMA; POSTMENOPAUSE; RASH; REVIEW; SIDE EFFECT; SPINE FRACTURE; SWEATING; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN; WRIST FRACTURE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; RECURRENCE; SURVIVAL RATE; TAMOXIFEN; TRIAZOLES;

EID: 22244489025     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.4.908563     Document Type: Review

References (37)

1. Bonneterre, B.J., Thürlimann, B., Robertson, J.F.R. et al. Anastrozole vs. tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000, 18: 3748-57.
2. Nabholtz, B.J.M., Buzdar, A., Pollak, M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Results of a North American Multicenter Randomized Trial. J Clin Oncol 2000, 18: 3758-67.
3. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects of long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 2000, 355: 1757-70.
4. Anderson, W.F., Chatterjee, M., Ershler, W.B. et al. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Research Treatment 2002, 76: 27-36.
5. The ATAC Trialists' Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-group of the 'Arimidex' and Tamoxifen Alone or in Combination (ATAC) trial. Br J Cancer 2001, 85: 317-24.
6. Buzdar, A., Jonat, W., Howell, A. et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 1996, 14: 2000-11.
7. Jonat, W., Howell, A., Blomqvist, C. et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996, 32A: 404-12.
8. Buzdar, A.U., Jonat, W., Howell, A. et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998, 83: 1142-52.
9. Dombernowsky, P., Smith, I., Falkson, G. et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16: 453-61.
10. Goss, P.E., Winer, E.P., Tannock, I.F., Schwartz, L.H. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol 1999, 17: 52-63.
11. Kaufmann, M., Bajetta, E., Dirix, L.Y. et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 2000, 18: 1399-411.
12. Thürlimann, B., Castiglione, M., Hsu-Schmitz, S.F. et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment - The Swiss Group for Clinical Cancer Res. Eur J Cancer 1997, 33: 1017-24.
13. Tobias, J.S., Howell, A. An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2004, 40: 1913.
14. Sainsbury, R. Aromatase inhibition in the treatment of advanced breast cancer: Is there a relationship between potency and clinical efficacy? Br J Cancer 2004, 90: 1733-9.
15. Rose, C., Vtoraya, O., Pluzanska, A. et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003, 39: 2318-27.
16. Bonneterre, J., Buzdar, A., Nabholtz, J.M. et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis. Cancer 2001, 92: 2247-58.
17. Nabholtz, J.M., Bonneterre, J., Buzdar, A. et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results. Eur J Cancer 2003, 12: 1684-89.
18. Buzdar, A.U., Vergote, I., Sainsbury, R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women. Breast J 2004, 10: 211-17.
19. Thurlimann, B., Hess, D., Koberle, D. et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - A sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004, 85: 247-54.
20. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002, 359: 2131-9.
21. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analysis. Cancer 2003, 98: 1802-10.
22. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of five years' adjuvant treatment for breast cancer. Lancet 2005, 365: 60-2.
23. Dowsett, M., Martin, L.A., Johnston, S., Smith, I.E. Predictors of resistance to hormonal therapy in breast cancer. Eur J Cancer Suppl 2004, 2: 43-4.
24. Howell, A., on behalf of the ATAC Trialists' Group. ATAC ('Arimidex', Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. Breast Cancer Res Treat 2004, 88 (Suppl 1): S7. Abstract 1.
25. Deitcher, S.R., Gomes, M.P.V. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: A systematic review. Cancer 2004, 101: 439-49.
26. Fallow-field, L., David, C., Cuzick, J. et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin One 2004, 22: 4261-71.
27. Zielinski, S.L. ASCO recommends aromatase inhibitors for adjuvant therapy for breast cancer. J Nat Cancer Institute 2004, 96: 1811.
28. Paepke, S., Harbeck, M., Jacobs, V.R. et al. Overview of neoadjuvant endocrine therapy for receptor positive breast cancer in post menopausal women. Geburtshilfe und Frauenhilkunde 2004, 64: 1290-8.
29. Dixon, J.M. Neoadjuvant endocrine therapy in breast cancer. Eur J Cancer 2004, 2: 60-1.
30. Dixon, J.M., Jackson, J., Hills, M. et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004, 40: 2742-7.
31. Milla-Santos, A., Milla, L., Calvo, N. et al. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally advanced breast cancer. Anticancer Res 2004, 24: 1315-18.
32. Dowsett, M., Smith, I.E., Ebbs, S.R. et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005, 11(2, Suppl 2): S951-8.
33. Mouridsen, H.T., Rose, C., Brodie, A.M., Smith, I.E. Challenges in the endrocrine management of breast cancer. Breast 2003, 12(Suppl 2): S2-19.
34. Boccardo, F. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer 2004, 5(Suppl 1): S7-13.
35. Buzdar, A.U. Role of anastrozole in adjuvant therapy for postmenopausal patients. Sem Oncol 2003, 30: 21-9.
36. Boccardo, F., Rubagott, A., Amoroso, D. et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. 26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003.
37. Jakes, R., Kaufmann, M., Gnant, M. et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004, 88(Suppl 1): S7. Abstract 2.